Bio-Path begins patient dosing in amended Phase 2 Prexigebersen trial
Category: #health  By Mateen Dalal  Date: 2019-08-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bio-Path begins patient dosing in amended Phase 2 Prexigebersen trial

The trial focuses on the effects of Prexigebersen when combined with Decitabine and Venetoclax on AML patients.

Bio-Path Holdings, Inc., a biotechnology company renowned for creating therapeutic nucleic acid anticancer drugs, has recently announced that it has initiated patient dosing in the firm’s amended Phase 2 Prexigebersen trial targeted towards treating AML (Acute Myeloid Leukemia).

According to reliable sources, a key update in the amended Phase 2 study is the involvement of patients with refractory/relapsed AML and high-risk MDS (Myelodysplastic Syndrome). The newly streamlined Phase 2 clinical trial has two groups of patients, first being unsupervised AML patients with the addition of high-risk MDS patients, and the second compromises of relapsed/refractory AML patients and high-risk MDS patients.

Moreover, the amended Phase 2 study will carry on assessing the safety of prexigebersen when combined with decitabine in both groups of patients at a dose of 60 mg/m2. The study will also involve a sum of six evaluable patients for checking the safety of decitabine and prexigebersen.

Reportedly, the company has managed to register five evaluable patients as for now including two patients who are currently undergoing the amended Phase 2 trial and three untreated AML patients who have previously received a therapy before amending the trial.

Furthermore, after assuming an effective completion of the safety assessment, the trials will tweak the testing of both groups of patients by combining venetoclax to the decitabine/prexigebersen combination treatment following which it plans to initiate the efficacy segment of this trial.

Sources cite that it is expected that each group will involve an interim assessment of 19 evaluable patients that would evaluate if the treatment efficacy of the combination of decitabine/ prexigebersen / venetoclax surpasses the efficacy of existing standard-of-care therapy with statistical consequence.

Commenting on the announcement, Peter Nielsen, President and Chief Executive Officer, Bio-Path, said that the company is excited to complete the dosing of the first patient in its amended clinical trial and is assured that the modification made to the protocol will effectively demonstrate the potential of prexigebersen in numerous cancer indications which have limited treatment options.

Source Credit: http://www.biopathholdings.com/wp-content/uploads/2019/08/BPTH_Patient_Dosing_in_Amended_AML_Trial.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Novo Nordisk and Medtronic team up to offer digital diabetes solutions
Novo Nordisk and Medtronic team up to offer digital diabetes solutions
By Mateen Dalal

With growing population of diabetic patients, diabetes management is becoming a daunting activity. Sugar level management and insulin injections tracking is a difficult work. Thus, leading pharmaceutical companies are collaborating with medical devic...

Akesis unveils its advanced Galaxy™ RTi and Gemini360 at ASTRO 2019
Akesis unveils its advanced Galaxy™ RTi and Gemini360 at ASTRO 2019
By Mateen Dalal

The healthcare company will showcase its drugs in the ASTRO annual meeting 2019 that could help offer improved efficiency and confidence in treatment delivery. Akesis, Inc., a hospital and healthcare company based in the U.S. that offers innovative...

Adverum reveals positive results from Phase 1 trial of ADVM-022
Adverum reveals positive results from Phase 1 trial of ADVM-022
By Mateen Dalal

The drug was well tolerated and was safe, and has shown the capacity to improve the treatment paradigm for patients with wet AMD. Adverum Biotechnologies, Inc., a company that develops medical therapies for ocular and rare diseases, recently announc...